Hudson Bay Capital Management LP grew its stake in shares of GSK plc (NYSE:GSK - Free Report) by 650.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 75,000 shares of the pharmaceutical company's stock after purchasing an additional 65,000 shares during the period. Hudson Bay Capital Management LP's holdings in GSK were worth $2,536,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Grimes & Company Inc. purchased a new stake in shares of GSK during the 4th quarter worth $4,731,000. Strategic Financial Concepts LLC purchased a new stake in shares of GSK in the 4th quarter worth about $4,033,000. Kempner Capital Management Inc. boosted its position in shares of GSK by 142.7% in the 4th quarter. Kempner Capital Management Inc. now owns 183,080 shares of the pharmaceutical company's stock worth $6,192,000 after buying an additional 107,648 shares in the last quarter. Stockman Wealth Management Inc. boosted its position in shares of GSK by 3.7% in the 4th quarter. Stockman Wealth Management Inc. now owns 217,200 shares of the pharmaceutical company's stock worth $7,346,000 after buying an additional 7,683 shares in the last quarter. Finally, MADDEN SECURITIES Corp purchased a new stake in shares of GSK in the 4th quarter worth about $2,957,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.
GSK Trading Up 0.2%
Shares of GSK stock traded up $0.07 during trading hours on Friday, hitting $37.64. 7,221,976 shares of the company were exchanged, compared to its average volume of 4,839,524. The firm has a market cap of $77.65 billion, a PE ratio of 23.67, a PEG ratio of 1.12 and a beta of 0.51. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.80. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a fifty day moving average of $37.39 and a 200 day moving average of $35.97.
GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The firm had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same quarter last year, the firm posted $0.43 earnings per share. GSK's revenue for the quarter was up 2.1% compared to the same quarter last year. Analysts expect that GSK plc will post 4.14 earnings per share for the current year.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a $0.4216 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. The ex-dividend date is Friday, May 16th. This represents a $1.69 annualized dividend and a yield of 4.48%. GSK's dividend payout ratio (DPR) is presently 86.60%.
Wall Street Analyst Weigh In
GSK has been the topic of several recent research reports. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. BNP Paribas initiated coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective on the stock. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $40.58.
Get Our Latest Analysis on GSK
About GSK
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
